REG - Physiomics PLC - Result of WRAP Retail Offer

PhysiomicsAnnouncement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260313:nRSM4924Wa&default-theme=true

RNS Number : 4924W  Physiomics PLC  13 March 2026

Unless otherwise defined herein, the capitalised terms used in this
announcement have the same meaning as those used in the Company's
announcements released on 10 March 2026.

 

13 March 2026

 

Physiomics plc

 

("Physiomics" or the "Company")

 

Result of WRAP Retail Offer

 

Physiomics plc (AIM: PYC), is pleased to announce, further to the
announcements made on 10 March 2026, the completion of the WRAP Retail Offer,
at the same issue price as the previously announced Placing (together the
"Fundraise"). The WRAP Retail Offer, which closed at 4.30 p.m. on 12 March
2026, has raised aggregate gross proceeds of £223,279.48 through the issue of
a total of 74,426,493 new Ordinary Shares, alongside the previously announced
Placing which raised gross proceeds of £449,999.88. The WRAP Retail Offer was
oversubscribed.

 

The Fundraise, which is conditional on certain resolutions being passed at the
General Meeting and on Admission, raised gross proceeds of, in aggregate,
£673,279.36, via the issue of 149,999,960 Placing Shares pursuant to the
Placing and 74,426,493 WRAP Retail Offer Shares pursuant to the WRAP Retail
Offer.

 

A further announcement regarding the enlarged issued share capital for the
purposes of the Financial Services Authority's Disclosure Guidance and
Transparency Rules will be made following completion of the Placing and the
WRAP Retail Offer.

 

The new Ordinary Shares to be issued pursuant to the WRAP Retail Offer (which
is conditional on the Placing and the passing of the resolutions at the
General Meeting) will be issued free of all liens, charges and encumbrances
and will, on Admission, rank pari passu in all respects with the new Ordinary
Shares to be issued pursuant to the Placing and the Company's existing
Ordinary Shares.

 

 

 

EXPECTED TIMETABLE OF EVENTS

 

 Latest time for receipt of Forms of Proxy and electronic proxy appointments:  10.00 a.m. on Wednesday 1 April 2026
 General Meeting:                                                              10.00 a.m. on Tuesday 7 April 2026
 Record Date for the Sub-Division                                              11.59 p.m. on Tuesday 7 April 2026
 Effective Date of the Sub-Division                                            11.59 p.m. on Tuesday 7 April 2026
 Admission of new Ordinary Shares and dealings commence on AIM                 8.00 a.m. on Wednesday 8 April 2026

 

For further information, please contact:

 Physiomics plc                        +44 (0) 1235 841575
 Dr Peter Sargent, CEO

 Hybridan LLP (Broker)                 +44 (0) 203 764 2341
 Claire Louise Noyce

 Strand Hanson Limited (NOMAD)         +44 (0) 20 7409 3494

 James Dance & James Bellman
 Winterflood Retail Access Platform    WRAP@winterflood.com
 Sophia Bechev & Kaitlan Billings      +44 (0)203 8100 0000

 

Further information on the Company can be found on its website at
www.physiomics.co.uk

 

The Company's LEI is 213800A71DSZ6ABMTQ91.

 

Notes to Editor

 

About Physiomics

 

Physiomics plc combines expertise across Modelling & Simulation,
Biostatistics, Data Science and Bioinformatics, together with deep
biology expertise, to help biotech and pharma companies streamline their drug
development journeys. Our approach is to help derive insight from all
relevant and often disparate data in order to de-risk decision making and
optimise research design across discovery, pre-clinical and clinical
studies. Through use of cutting-edge computational
tools, bespoke models and our proprietary Virtual Tumour technology,
the Physiomics team has informed the development of over 140 commercial
projects, with over 125 targets and drugs modelled. Clients include
Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics &
CRUK.

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ROIAKBBKBBKBAND



            Copyright 2019 Regulatory News Service, all rights reserved